Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,631–1,640 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1631
- Medicine slug
- vigabatrin
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 0.96
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 24
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 24 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0afdc84c-f8ec-330a-31c9-fac4ed256931 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee835fb6-2b2b-40c4-b6d7-0ad0e790cda8 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04fef2ec-c275-405d-91b1-99a74ee8caa2 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9791494f-492b-487a-8211-7747fb57923e (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dc7bd15-2636-4d58-b651-dd117ca43dbd (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ed8d293-b7d8-4c66-9c31-8075e6f99092 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c0bf4fb-b234-4053-9163-1e8d0142d718 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5d389d2-d0e1-4395-a2a2-b552808e7f98 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a88ac1b4-e2c9-45c0-b321-4785902172e3 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:823cc915-0350-4780-85ed-cd1c338e429d (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b8fb137-848b-45fd-9107-a6db5a675360 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c97ce40c-1c5a-479d-9188-5ce03cf7e065 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aaea88b-e0fd-45e3-bb02-604bf8ee9b5b (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f7f049-78c2-47c2-a66e-ec662ba48a98 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93ba3894-fd97-4432-9f2d-e7050371e91f (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7cbc0a5-8c28-4451-9176-b608e228ba66 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bda491b6-47ba-400b-9816-b6d15c6e2683 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6be436e-46c7-e9ab-0fcf-e8d04dc12b72 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d3fc853-1b2d-47ad-a4f2-f11505601bc2 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c99000-fc0c-4083-b620-ba9ac821f8ac (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d818a-4f4e-4675-98c6-91db0294e63c (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd5ebc7a-8d5b-46b4-ad9b-e4a25fa3e26c (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e5e7554-d0f4-47f7-a434-cc5ca5a9826f (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8406bd5a-8887-4579-a11e-5ab449c58963 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 1 hour for children and adolescents (3 years to 16 years of age) and adults, and approximately 2.5 hours for infants (5 months to 2 years of age).
2.5 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d3d6316-33ab-41e8-9485-4495c218be56 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
The time to maximum concentration (T max ) is approximately 2.5 hours for infants (5 months to 2 years of age).
Projected row 1632
- Medicine slug
- vigabatrin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
1.1 L/kg
- Numeric value
- 1.1
- Unit
- L/kg
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0afdc84c-f8ec-330a-31c9-fac4ed256931 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee835fb6-2b2b-40c4-b6d7-0ad0e790cda8 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04fef2ec-c275-405d-91b1-99a74ee8caa2 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9791494f-492b-487a-8211-7747fb57923e (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8dc7bd15-2636-4d58-b651-dd117ca43dbd (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ed8d293-b7d8-4c66-9c31-8075e6f99092 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c0bf4fb-b234-4053-9163-1e8d0142d718 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5d389d2-d0e1-4395-a2a2-b552808e7f98 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a88ac1b4-e2c9-45c0-b321-4785902172e3 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:823cc915-0350-4780-85ed-cd1c338e429d (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b8fb137-848b-45fd-9107-a6db5a675360 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c97ce40c-1c5a-479d-9188-5ce03cf7e065 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d3d6316-33ab-41e8-9485-4495c218be56 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4aaea88b-e0fd-45e3-bb02-604bf8ee9b5b (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01f7f049-78c2-47c2-a66e-ec662ba48a98 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93ba3894-fd97-4432-9f2d-e7050371e91f (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7cbc0a5-8c28-4451-9176-b608e228ba66 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bda491b6-47ba-400b-9816-b6d15c6e2683 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6be436e-46c7-e9ab-0fcf-e8d04dc12b72 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d3fc853-1b2d-47ad-a4f2-f11505601bc2 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9c99000-fc0c-4083-b620-ba9ac821f8ac (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:082d818a-4f4e-4675-98c6-91db0294e63c (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd5ebc7a-8d5b-46b4-ad9b-e4a25fa3e26c (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e5e7554-d0f4-47f7-a434-cc5ca5a9826f (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8406bd5a-8887-4579-a11e-5ab449c58963 (opens source in a new tab)
Vigabatrin label
Version not recorded · Effective date not recorded
Vigabatrin is widely distributed throughout the body; mean steady-state volume of distribution is 1.1 L/kg (CV = 20%).
Projected row 1633
- Medicine slug
- vilazodone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
72%
- Numeric value
- 72
- Unit
- %
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b8ca479-72e9-2431-e063-6394a90af7ff (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0374fbb1-b0fb-4150-b1e7-92e2b0d32ecf (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone is 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f68720fd-9122-4922-b472-733da8bd0a00 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a4745a0-de23-4b40-923e-0d7dfe6b8634 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a70fd858-cbef-7336-d7ce-c78499031644 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b95b850-8bdf-4255-a691-783d1a94bd07 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone is 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f917f30d-f2a7-43eb-836f-53eaa2a31cb0 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Absorption Vilazodone concentrations peaked at a median of 4 to 5 hours (T max ) after vilazodone administration and declined with a terminal half-life of approximately 25 hours.The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c55ccfb-c4cf-11df-851a-0800200c9a66 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.Vilazodone AUC and C max in the fasted state can be decreased by approximately 50% and 60%, respectively, compared to the fed state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:061efdcc-40ea-4647-8cc8-01cd1ccca68b (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:701c8b84-13ae-4adb-af7a-304bf1f21e3b (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:658c4bc1-4128-4e0e-8852-b5f68880e8d7 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1d8b51c-823b-4702-a726-a7530abd8957 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3e167cd-7f56-45eb-80df-a60fa1392e57 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
The absolute bioavailability of vilazodone was 72% with food.
Projected row 1634
- Medicine slug
- vilazodone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 1
- Recorded readings
25 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b8ca479-72e9-2431-e063-6394a90af7ff (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0374fbb1-b0fb-4150-b1e7-92e2b0d32ecf (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f68720fd-9122-4922-b472-733da8bd0a00 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a4745a0-de23-4b40-923e-0d7dfe6b8634 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a70fd858-cbef-7336-d7ce-c78499031644 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b95b850-8bdf-4255-a691-783d1a94bd07 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f917f30d-f2a7-43eb-836f-53eaa2a31cb0 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c55ccfb-c4cf-11df-851a-0800200c9a66 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:061efdcc-40ea-4647-8cc8-01cd1ccca68b (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:701c8b84-13ae-4adb-af7a-304bf1f21e3b (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:658c4bc1-4128-4e0e-8852-b5f68880e8d7 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1d8b51c-823b-4702-a726-a7530abd8957 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3e167cd-7f56-45eb-80df-a60fa1392e57 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Elimination of vilazodone is primarily by hepatic metabolism with a terminal half-life of approximately 25 hours.
Projected row 1635
- Medicine slug
- vilazodone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
25 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f917f30d-f2a7-43eb-836f-53eaa2a31cb0 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Absorption Vilazodone concentrations peaked at a median of 4 to 5 hours (T max ) after vilazodone administration and declined with a terminal half-life of approximately 25 hours.The absolute bioavailability of vilazodone was 72% with food.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c55ccfb-c4cf-11df-851a-0800200c9a66 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Absorption Vilazodone concentrations peaked at a median of 4-5 hours (T max ) after VIIBRYD administration and declined with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:658c4bc1-4128-4e0e-8852-b5f68880e8d7 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Absorption Vilazodone concentrations peaked at a median of 4 to 5 hours (Tmax) after vilazodone administration and declined with a terminal half-life of approximately 25 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1d8b51c-823b-4702-a726-a7530abd8957 (opens source in a new tab)
Vilazodone label
Version not recorded · Effective date not recorded
Absorption Vilazodone concentrations peaked at a median of 4 to 5 hours (Tmax) after vilazodone administration and declined with a terminal half-life of approximately 25 hours.
Projected row 1636
- Medicine slug
- vinorelbine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
27.7 to 43.6 hours
- Numeric value
- 27.7
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a70995-e04d-4044-b1dc-c9aa27460397 (opens source in a new tab)
Vinorelbine label
Version not recorded · Effective date not recorded
Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd3dcc9a-e40c-4677-9ee6-f318e7c7d835 (opens source in a new tab)
Vinorelbine label
Version not recorded · Effective date not recorded
Elimination The terminal phase half-life averages 27.7 to 43.6 hours and the mean plasma clearance ranges from 0.97 to 1.26 L/hr/kg.
Projected row 1637
- Medicine slug
- vinorelbine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
25.4 to 40.1 L/kg
- Numeric value
- 25.4
- Unit
- L/kg
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10a70995-e04d-4044-b1dc-c9aa27460397 (opens source in a new tab)
Vinorelbine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution (V SS ) values range from 25.4 to 40.1 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd3dcc9a-e40c-4677-9ee6-f318e7c7d835 (opens source in a new tab)
Vinorelbine label
Version not recorded · Effective date not recorded
Distribution Steady-state volume of distribution (V SS ) values range from 25.4 to 40.1 L/kg.
Projected row 1638
- Medicine slug
- voriconazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 43
- Source count
- 42
- Agreement rate
- 1
- Recorded readings
96%
- Numeric value
- 96
- Unit
- %
- Source records
- 42
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 42 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67c174da-41b8-4738-8a22-dd814b8e96b8 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N = 207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75fcbea8-8eeb-4528-b7d9-a059dd25da83 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bda70104-d84b-4d3f-9ca0-5f4f1ca816ad (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a81e485-7f26-45b6-bfd7-6114afb7def9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171272c7-d76e-4352-81bc-fcb40386d7d0 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N = 207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:711e5a1b-8c40-4b18-9f4f-12c8ab351012 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6624a9-0b73-4a21-bf13-a8add2081d02 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff10d69-e334-42bd-baed-7d9d5feef6aa (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe672ff-2cef-4f88-ab85-5a4b586da20d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16a80777-f1f3-45bb-a312-998b07767fe3 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e698e5c7-f4a5-2beb-e053-2995a90a256b (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8379ac92-53cd-46db-8642-017f11830a86 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4c934c0-c1bb-4b0a-bc32-fb9e77ef65fc (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8de04a0-238d-4e0b-b0d9-7f7878b149d4 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35098192-3bcb-9111-e063-6394a90ae8ea (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b38165a5-d8d4-4579-a49a-fbe92e764089 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a1a792-141b-42e8-8bd1-884e4408eb8a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eb8d91-5abd-4fdb-a331-dacc960a95d9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cbac6ad-0faa-4181-a830-27a9f1536b7a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08d08721-1f4c-478a-8abf-d9c402d50553 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fceb92c5-5269-46e2-ac5f-547b2f77953d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3af8cfe6-1c0d-4b57-ae31-05cffa64132e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N = 207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac26bcd-7a59-401f-9f66-a0649767cece (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:511fa110-e4cc-4498-80db-03b7cddb1d5a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:796cad15-2aef-4823-917d-17b822a6916e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3b67028-f8a0-4a93-9e73-9e8940c22c4a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b262849-9a29-44a2-9b9d-2378f771379c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce3ef5cf-3087-4d92-9d94-9eb8287228db (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d5b9457-ac38-4f17-854d-e394c00e273c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dcf3ae-6d6b-46fe-a88e-ec65f2de332e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2b3c0b3-02a6-45c3-a8ea-05d210dc9108 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bceb01d5-c2d9-436d-896f-26643fa22d50 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e37525e8-afb4-4583-b2de-af4aab9040d7 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ecce53-57b8-4af1-b4ac-7d37eb25711f (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3266cf9b-e648-1ff2-e063-6394a90a0487 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8217c621-976e-450b-8f48-5dc3119dc53c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d962d459-254f-4b78-ae28-7d9ec5d4e4d5 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:393a81ba-7d51-450e-8d20-23287767c002 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f2e0784-8e48-f565-e053-2991aa0a0746 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f25c6b-f075-42dc-ae05-63b5bf410929 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N = 207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620b2d7-3c2b-4252-8cfc-2f322d624435 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%).
Projected row 1639
- Medicine slug
- voriconazole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 43
- Source count
- 43
- Agreement rate
- 1
- Recorded readings
58%
- Numeric value
- 58
- Unit
- %
- Source records
- 43
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 43 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ec6eda2-2f15-423b-9ec6-819379a426e1 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67c174da-41b8-4738-8a22-dd814b8e96b8 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75fcbea8-8eeb-4528-b7d9-a059dd25da83 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bda70104-d84b-4d3f-9ca0-5f4f1ca816ad (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a81e485-7f26-45b6-bfd7-6114afb7def9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171272c7-d76e-4352-81bc-fcb40386d7d0 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:711e5a1b-8c40-4b18-9f4f-12c8ab351012 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6624a9-0b73-4a21-bf13-a8add2081d02 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff10d69-e334-42bd-baed-7d9d5feef6aa (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe672ff-2cef-4f88-ab85-5a4b586da20d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16a80777-f1f3-45bb-a312-998b07767fe3 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e698e5c7-f4a5-2beb-e053-2995a90a256b (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8379ac92-53cd-46db-8642-017f11830a86 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4c934c0-c1bb-4b0a-bc32-fb9e77ef65fc (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8de04a0-238d-4e0b-b0d9-7f7878b149d4 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35098192-3bcb-9111-e063-6394a90ae8ea (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b38165a5-d8d4-4579-a49a-fbe92e764089 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a1a792-141b-42e8-8bd1-884e4408eb8a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eb8d91-5abd-4fdb-a331-dacc960a95d9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cbac6ad-0faa-4181-a830-27a9f1536b7a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08d08721-1f4c-478a-8abf-d9c402d50553 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fceb92c5-5269-46e2-ac5f-547b2f77953d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3af8cfe6-1c0d-4b57-ae31-05cffa64132e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac26bcd-7a59-401f-9f66-a0649767cece (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:511fa110-e4cc-4498-80db-03b7cddb1d5a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:796cad15-2aef-4823-917d-17b822a6916e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3b67028-f8a0-4a93-9e73-9e8940c22c4a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b262849-9a29-44a2-9b9d-2378f771379c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce3ef5cf-3087-4d92-9d94-9eb8287228db (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d5b9457-ac38-4f17-854d-e394c00e273c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dcf3ae-6d6b-46fe-a88e-ec65f2de332e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2b3c0b3-02a6-45c3-a8ea-05d210dc9108 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bceb01d5-c2d9-436d-896f-26643fa22d50 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e37525e8-afb4-4583-b2de-af4aab9040d7 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ecce53-57b8-4af1-b4ac-7d37eb25711f (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3266cf9b-e648-1ff2-e063-6394a90a0487 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8217c621-976e-450b-8f48-5dc3119dc53c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d962d459-254f-4b78-ae28-7d9ec5d4e4d5 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:393a81ba-7d51-450e-8d20-23287767c002 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9–15 µg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f2e0784-8e48-f565-e053-2991aa0a0746 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mcg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f25c6b-f075-42dc-ae05-63b5bf410929 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620b2d7-3c2b-4252-8cfc-2f322d624435 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9 to 15 mcg/mL).
Projected row 1640
- Medicine slug
- voriconazole
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 43
- Source count
- 43
- Agreement rate
- 1
- Recorded readings
4.6 L/kg
- Numeric value
- 4.6
- Unit
- L/kg
- Source records
- 43
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 43 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ec6eda2-2f15-423b-9ec6-819379a426e1 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e648a0e4-f324-49dc-a8f6-cf25ff3b2dfe (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67c174da-41b8-4738-8a22-dd814b8e96b8 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75fcbea8-8eeb-4528-b7d9-a059dd25da83 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bda70104-d84b-4d3f-9ca0-5f4f1ca816ad (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a81e485-7f26-45b6-bfd7-6114afb7def9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:171272c7-d76e-4352-81bc-fcb40386d7d0 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:711e5a1b-8c40-4b18-9f4f-12c8ab351012 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6624a9-0b73-4a21-bf13-a8add2081d02 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff10d69-e334-42bd-baed-7d9d5feef6aa (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fe672ff-2cef-4f88-ab85-5a4b586da20d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16a80777-f1f3-45bb-a312-998b07767fe3 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e698e5c7-f4a5-2beb-e053-2995a90a256b (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8379ac92-53cd-46db-8642-017f11830a86 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4c934c0-c1bb-4b0a-bc32-fb9e77ef65fc (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8de04a0-238d-4e0b-b0d9-7f7878b149d4 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35098192-3bcb-9111-e063-6394a90ae8ea (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b38165a5-d8d4-4579-a49a-fbe92e764089 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a1a792-141b-42e8-8bd1-884e4408eb8a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25eb8d91-5abd-4fdb-a331-dacc960a95d9 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cbac6ad-0faa-4181-a830-27a9f1536b7a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08d08721-1f4c-478a-8abf-d9c402d50553 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fceb92c5-5269-46e2-ac5f-547b2f77953d (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3af8cfe6-1c0d-4b57-ae31-05cffa64132e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dac26bcd-7a59-401f-9f66-a0649767cece (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:511fa110-e4cc-4498-80db-03b7cddb1d5a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:796cad15-2aef-4823-917d-17b822a6916e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3b67028-f8a0-4a93-9e73-9e8940c22c4a (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b262849-9a29-44a2-9b9d-2378f771379c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce3ef5cf-3087-4d92-9d94-9eb8287228db (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d5b9457-ac38-4f17-854d-e394c00e273c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dcf3ae-6d6b-46fe-a88e-ec65f2de332e (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2b3c0b3-02a6-45c3-a8ea-05d210dc9108 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bceb01d5-c2d9-436d-896f-26643fa22d50 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e37525e8-afb4-4583-b2de-af4aab9040d7 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53ecce53-57b8-4af1-b4ac-7d37eb25711f (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3266cf9b-e648-1ff2-e063-6394a90a0487 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8217c621-976e-450b-8f48-5dc3119dc53c (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d962d459-254f-4b78-ae28-7d9ec5d4e4d5 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:393a81ba-7d51-450e-8d20-23287767c002 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f2e0784-8e48-f565-e053-2991aa0a0746 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23f25c6b-f075-42dc-ae05-63b5bf410929 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620b2d7-3c2b-4252-8cfc-2f322d624435 (opens source in a new tab)
Voriconazole label
Version not recorded · Effective date not recorded
Distribution The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1630Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.